Evaluation of the Efficacy and Safety of ToleraCell (Apoptotic Donor Leukocytes) and Induction Immunosuppression With Anti-CD40 Monoclonal Antibody DFI105, Sirolimus, Etanercept, and Tocilizumab for Induction of Tolerance to Islet Allotransplants in Subjects With Predominantly β-Cell Failure-mediated Type 2 Diabetes
Latest Information Update: 14 Dec 2023
At a glance
- Drugs DFI 105 (Primary) ; Etanercept (Primary) ; Sirolimus (Primary) ; Tocilizumab (Primary)
- Indications Type 2 diabetes mellitus
- Focus First in man; Pharmacodynamics; Therapeutic Use
- Sponsors DIABETES FREE
Most Recent Events
- 14 Dec 2023 New trial record